GenSight Biologics has announced the completion of a EUR 1,999,998 fundraising subscribed by existing shareholders, Invus and Alumni Capital. This fundraising follows previous rounds and aims to bolster the development of the company's gene therapies. CEO Laurence Rodriguez highlighted the confidence this investment brings to their strategic progress. The company focuses on therapies for retinal neurodegenerative diseases.
Who to call at GenSight Biologics, and when
A new round usually means GenSight Biologics is about to hire and buy. The teams that reach out first get the meeting.
An alert the day GenSight Biologics raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at GenSight Biologics, from your own LinkedIn network
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
GenSight Biologics
Location
Paris, Ile-de-France, France
About
GenSight Biologics is a clinical-stage biotechnology company discovering and developing novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system. GenSight Biologics’ pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics for retinitis pigmentosa, to help preserve or restore vision in patients suffering from severe degenerative retinal diseases. GenSight Biologics’ lead product candidate, GS010, is in Phase III trials in Leber’s Hereditary Optic Neuropathy (LHON), a rare mitochondrial disease that leads to irreversible low vision and legal blindness in teens and young adults. Using its gene therapy-based approach, GenSight Biologics’ product candidates are designed to be administered in a single treatment to each eye by intravitreal injection to offer patients a sustainable functional visual recovery.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment GenSight Biologics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
ParisBiotechnologyHealth CareTherapeuticsBiopharma